Galectin Therapeutics Inc. · NASDAQ:GALT
Galectin Therapeutics — Investor Presentation (February 2012)
26 slides from Galectin Therapeutics's investor presentation, Feb 14, 2012
Slide 1: Corporate Summary February 2012
Corporate Summary February 2012 OTC: GALT Exhibit 99.1
Slide 2: Forward Looking Statements
© 2012 Galectin Therapeutics OTC:GALT 2 Forward Looking Statements This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial pe
Slide 3: Highlights
HIGHLIGHTS Proprietary Compounds Validated Science Large Market Opportunities Intellectual Property Experienced Management Team © 2012 Galectin Therapeutics OTC:GALT 3 First in class, proprietary compounds that inhibit galectin proteins Novel class of safe, complex carbohydrate drugs GR-MD-02: Non-a
Slide 4: Experienced Management Team
© 2012 Galectin Therapeutics OTC:GALT 4 Peter G. Traber, MD President, CEO, CMO Anatole Klyosov, PhD Chief Scientist Eliezer Zomer, PhD EVP, Product Development Anthony Squeglia, MBA CFO Maureen Foley COO Elena Chekhova, PhD Program Manager Experienced Management Team Over 25 years experience in bio
Slide 5: NASH and Liver Fibrosis are Multi-Billion Dollar Markets in US Alone
© 2012 Galectin Therapeutics OTC:GALT 5 NASH and Liver Fibrosis are Multi- Billion Dollar Markets In US Alone Transplants (6,291*) Wait List (17,000**) Death From Cirrhosis (44,677 # ) Cirrhosis (400,000 ## ) NASH: 9-15 Million & * Performed in US in 2010 (UNOS) * * Prevalence in US 2010 (UNOS) The
Slide 6: Immune Enhancement is Synergistic With Many Emerging Cancer Immunotherapies
© 2012 Galectin Therapeutics OTC:GALT 6 Immune Enhancement is Synergistic With Many Emerging Cancer Immunotherapies Enhancing the ability of the immune system to recognize and kill tumor cells is a very active area in the personalized approach to cancer therapy Two agents have been approved for use
Slide 7: Science of Galectins
© 2012 Galectin Therapeutics OTC:GALT 7 Science of Galectins Galectin Function Galectin Inhibitors Liver Fibrosis Mechanism of Action Regulatory and Clinical Plan Competitive Positioning Immune Enhancement in Cancer Therapy Mechanism of Action Regulatory and Clinical Plan Competitive Positioning
Slide 8: Galectin Proteins Are Critical Participants In Pathogenesis of Many Fibrotic and Neoplastic Diseases
© 2012 Galectin Therapeutics OTC:GALT 8 Galectin Proteins Are Critical Participants In Pathogenesis of Many Fibrotic and Neoplastic Diseases PROMOTE PATHOLOGY Markedly Increased in: 1. Inflammation 2. Fibrosis 3. Cancer *Galectin-3 is key galectin in pathological processes Secreted Galectin Proteins
Slide 9: Galectin Inhibitors: A New Class of Pathology Modulators
© 2012 Galectin Therapeutics OTC:GALT 9 Galectin Proteins Galectin Inhibitor Galectin Inhibitors: A New Class of Pathology Modulators Novel complex carbohydrate drugs that target secreted and membrane-associated galectins by virtue of high molecular weight Strongest binding to galectin-3, most promi
Slide 10: Science of Galectins
© 2012 Galectin Therapeutics OTC:GALT 10 Science of Galectins Galectin Function Galectin Inhibitors Liver Fibrosis Mechanism of Action Regulatory and Clinical Plan Competitive Positioning Immune Enhancement in Cancer Therapy Mechanism of Action Regulatory and Clinical Plan Competitive Positioning
Slide 11: Galectin-3 Is A Critical Target For Therapy of Liver Fibrosis
© 2012 Galectin Therapeutics OTC:GALT 11 Galectin-3 Is A Critical Target For Therapy of Liver Fibrosis Galectin-3 is produced in large amounts by fibrotic liver (animal and human) Galectin-3 is essential in mice for the development of liver fibrosis. Fibrosis due to toxin exposure or fatty liver DOE
Slide 12: GR-MD-02 Effectively Treats Toxin-Induced Liver Fibrosis in Rats
© 2012 Galectin Therapeutics OTC:GALT 12 Galectin Inhibitor GR-MD-02 Effectively Treats Toxin-Induced Liver Fibrosis in Rats Galectin Therapeutics Data: Study performed under contract by Dr. Ji - yao Wang of Fudan University, Shanghai, China Liver Fibrosis, induced by injection of chemical toxin for
Slide 13: GR-MD-02 Prevents and Completely Reverses Fibrosis in NASH
© 2012 Galectin Therapeutics OTC:GALT 13 GR-MD-02 Prevents and Completely Reverses Fibrosis in Non-Alcoholic Steatohepatitis (NASH) normal mouse 0.33 GR-MD-02 also reduces fat, liver cell death, and inflammation Early Rx Late Rx
Slide 14: Fibrosis Development Program: GR-MD-02
© 2012 Galectin Therapeutics OTC:GALT 14 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2012 2013 2014 Post Transplant Fibrosis Phase II Post Tx Fibrosis Trial Phase I DE NASH NASH Fibrosis Development Program: GR-MD-02 Phase II NASH with Fibrosis Trial Plan to File Fast Track Designation Plan to File Orphan D
Slide 15: Competitive Positioning in NASH
© 2012 Galectin Therapeutics OTC:GALT 15 General Mechanism Examples Comments Competitive Positioning in NASH Treat Diabetes and Insulin Resistance Pioglitazone Failed to achieve significant endpoints in phase II and phase III clinical trials Inhibit Lipid Metabolism Aramchol Colesevelam Cholesterol
Slide 16: Science of Galectins
© 2012 Galectin Therapeutics OTC:GALT 16 Science of Galectins Galectin Function Galectin Inhibitors Liver Fibrosis Mechanism of Action Regulatory and Clinical Plan Competitive Positioning Immune Enhancement in Cancer Therapy Mechanism of Action Regulatory and Clinical Plan Competitive Positioning
Slide 17: Most Cancers Secrete Large Amounts of Galectins
© 2012 Galectin Therapeutics OTC:GALT 17 The Vast Majority of Cancers Secrete Large Amounts of Galectins Which Have Multiple Roles in Tumor Pathogenesis Tumor cell invasion: extracellular matrix adhesion & detachment Stromal cell function Metastasis: cell invasion and migration Angiogenesis Tumor im
Slide 18: GM-CT-01 Has Proven Safe in Over Human Subjects
© 2012 Galectin Therapeutics OTC:GALT 18 GM-CT-01 Has Proven Safe in Over 100 Human Subjects and Has Been Shown to Have Effect In Colorectal Cancer Cancer Trial (DAVFU-003) Day 0 Day 28 GM-CT-01 Chemo (5-FU) Phase II trial of 5-FU plus GM-CT-01 in line 3/4 therapy of metastatic colorectal cancer 6.7
Slide 19: Tumor Infiltrating T-Cells Are Able to Recognize and Kill Tumor Cells
© 2012 Galectin Therapeutics OTC:GALT 19 Tumor Infiltrating T-Cells Are Able to Recognize and Kill Tumor Cells Experiments performed by Dr. Pierre van der Bruggen of the Ludwig Institute in Brussels, Belgium in collaboration with Galectin Therapeutics Cytokines (e.g., INF) Kill tumor cells Tumor-Inf
Slide 20: Galectins Effect: Tumors Inactivate Tumor-Infiltrating T-Cells
© 2012 Galectin Therapeutics OTC:GALT 20 “Galectins Effect”: Tumors Inactivate Tumor-Infiltrating T-Cells Through Secretion of Galectin-3 Which Coats Surface of T-Cells and Alters Receptor Function Experiments performed by Dr. Pierre van der Bruggen of the Ludwig Institute in Brussels, Belgium in co
Slide 21: GM-CT-01 Blocks the Galectins Effect
© 2012 Galectin Therapeutics OTC:GALT 21 GM-CT-01 Blocks the “Galectins Effect” and the Restores the Ability of Tumor-Infiltrating T-Cells to Kill Tumor Cells Experiments performed by Dr. Pierre van der Bruggen of the Ludwig Institute in Brussels, Belgium in collaboration with Galectin Therapeutics
Slide 22: Melanoma Proof of Concept
© 2012 Galectin Therapeutics OTC:GALT 22 Melanoma “Proof of Concept” Clinical Trial Design Phase I/II study of peptide vaccination associated with GM-CT-01 in patients with advanced metastatic melanoma IMPD approved by EMA Group 2 patients have additional injection of GM-CT-01 in cutaneous tumors
Slide 23: Immune Enhancement Development Program
© 2012 Galectin Therapeutics OTC:GALT 23 Q1 Q2 Q4 Q1 Q3 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Tumor Immune Enhancement Development Program 2012 2013 2014 Preclinical Efficacy Studies GM-CT-01 Phase I/II Melanoma Trial Top line results in Stage 1 Top line results in Stage 2 Efficacy in immune competent mice with syng
Slide 24: Competitive Positioning In Tumor Immunotherapy
© 2012 Galectin Therapeutics OTC:GALT 24 Competitive Positioning In Tumor Immunotherapy Market for tumor vaccines is expected to grow to $7B by 2015. If ipilimumab (Yervoy, BMS) is included, market is even larger. Blocking the “Galectin Effect” would be synergistic with all types of tumor vaccines o
Slide 25: Science of Galectins
© 2012 Galectin Therapeutics OTC:GALT 25 Science of Galectins Galectin Function Galectin Inhibitors Liver Fibrosis Mechanism of Action Regulatory and Clinical Plan Competitive Positioning Immune Enhancement in Cancer Therapy Mechanism of Action Regulatory and Clinical Plan Competitive Positioning
Slide 26: Summary
SUMMARY Novel Mechanism & Compounds Large Market Opportunities Near Term Milestones Experienced Management Team and Board © 2012 Galectin Therapeutics OTC:GALT 26 First in class, proprietary compounds that inhibit galectin proteins. Novel class of safe, complex carbohydrate drugs. Strong patent posi
Galectin Therapeutics — Investor Presentation (February 2012) on 6ix